New
HealthMore in Health→
Tumor Microenvironment Cell Types May Predict Tamoxifen Benefit in Breast Cancer
Key Takeaways
- Study analyzed tumor samples from 513 postmenopausal women with ER+/HER2- breast cancer from the STO-3 trial.
- Patients with low immune cell abundance in the tumor microenvironment had greater long-term benefit from tamoxifen.
- Blood vessel and connective tissue cell levels also influenced treatment outcomes.
- Findings may help personalize hormone therapy decisions.
DE
DT Editorial Team··via medicalxpress.com